What type of study is this?

This is a Animal Study study (also classified as: Human Clinical Trial).

December 8, 2025Advanced ScienceOpen Access

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

View Full Paper

Ask AI

Bookmark

Authors

Adoptive immunotherapy shows 100% response in patients with CMV or EBV infections, highlighting T memory stem cells' significance.

Adoptive immunotherapy achieves a 100% overall response rate in patients with viral infections, specifically CMV and EBV.
The complete response rate reached 70% in a phase I clinical trial, underscoring the potential of TSCM-enriched VSTs.
Assessment included a murine model showing enhanced protection against tumors by CD8⁺ TSCM VSTs compared to other VST types.
Enhanced Wnt signaling and reduced exhaustion in TSCM indicate a promising direction for antiviral therapies enhancing durability.

Cao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark